Healius Ltd

HLS

Company Profile

  • Business description

    Healius is Australia’s second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.

  • Contact

    161 Castlereagh Street
    Level 22
    SydneyNSW2000
    AUS

    T: +61 294329400

    E: [email protected]

    https://www.healius.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    30 June 2025

    Employees

    10,500

Healius Ltd News & Analysis

stocks

Ask the analyst: Why have Healius shares struggled so much?

Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.
stocks

Top-rated funds love these 3 cheap ASX shares

These companies could offer good value and, as of the latest data and have the stamp of approval from Morningstar Gold Medalist equity funds.
stocks

Undervalued ASX 200 share in net cash position after sale of business

Proceeds from the sale don’t make up for lost earnings. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,471.5018.800.22%
CAC 407,282.6910.370.14%
DAX 4019,848.7735.98-0.18%
Dow JONES (US)43,302.085.050.01%
FTSE 1008,136.9934.270.42%
HKSE20,098.29215.161.08%
NASDAQ20,018.2912.83-0.06%
Nikkei 22539,568.06437.631.12%
NZX 50 Index13,074.7486.710.67%
S&P 5006,036.513.53-0.06%
S&P/ASX 2008,220.9019.300.24%
SSE Composite Index3,393.5342.271.26%

Market Movers